IRADIMED CORPORATION financials

  1. Home
  2. Financials
  3. IRMD
IRMD CIK 0001325618

Source: EDGAR filings · Built 2026-06-02T03:19:31Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 17.18M 17.62M 6.02M 9.22M 10.78M 5.37M
EBITDA 27.31M 22.78M 20.80M 16.30M 11.22M 582.73K
Working Capital 71.02M 66.73M 59.67M 68.94M 69.42M 58.82M
Net Debt — -52.08M -47.72M -55.35M -59.52M -47.35M
Gross Margin 76.75% 76.94% 76.50% 77.45% 76.65% 74.33%
Operating Margin 31.20% 29.99% 30.56% 29.32% 23.48% -2.38%
Net Margin 26.82% 26.26% 26.22% 24.07% 22.30% 4.32%
Return on Equity (ROE) 23.76% 22.15% 24.07% 17.41% 12.92% 2.23%
Return on Assets (ROA) 20.67% 19.56% 18.66% 15.00% 11.25% 1.93%
Current Ratio 7.98× 8.84× 4.65× 9.06× 11.18× 12.96×
Debt-to-Equity — 0.00× 0.03× 0.04× 0.03× 0.04×
Effective Tax Rate 20.74% 20.77% 20.91% 20.72% 5.19% 321.92%
Cash Conversion Ratio 1.11× 1.33× 0.78× 0.78× 1.21× 4.25×
Accruals Ratio -0.02× -0.07× 0.04× 0.03× -0.02× -0.06×
SBC % of Revenue 3.48% 3.45% 3.34% 2.62% 3.49% 12.49%
CapEx Coverage 3.21× 3.20× 1.81× 12.20× 23.34× 13.13×
Free Cash Flow Per Share $1.34 $1.38 $0.47 $0.73 $0.86 $0.43

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 55.59× 36.67× 35.16× 27.74× 62.45× 207.27×
P/FCF 72.78× 39.91× 100.25× 38.77× 54.00× 52.78×
FCF Yield 1.37% 2.51% 1.00% 2.58% 1.85% 1.89%
EV / EBITDA 43.65× 28.40× 26.60× 18.46× 46.34× 400.32×
P/S 14.84× 9.54× 9.17× 6.68× 13.86× 8.85×
P/B 13.14× 8.05× 8.41× 4.83× 8.03× 4.57×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 83.81M 73.24M 65.56M 53.30M 41.81M 31.72M
Revenues 83.81M 73.24M 65.56M 53.30M 41.81M 31.72M
Cost of Revenue 19.49M 16.89M 15.40M 12.02M 9.76M 8.14M
Gross Profit 64.32M 56.35M 50.16M 41.28M 32.05M 23.57M
Research and Development Expense 2.98M 2.83M 2.86M 2.28M 1.91M 1.90M
Operating Expenses 38.18M 34.38M 30.12M 25.65M 22.23M 24.33M
Operating Income (Loss) 26.15M 21.96M 20.04M 15.63M 9.82M -756.09K
Income Tax Expense (Benefit) 5.88M 5.04M 4.55M 3.35M 510.82K -1.99M
Net Income (Loss) Attributable to Parent 22.48M 19.23M 17.19M 12.83M 9.33M 1.37M
Earnings Per Share, Basic $1.77 $1.52 $1.36 $1.02 $0.76 $0.11
Weighted Average Number of Shares Outstanding, Basic 12.72M 12.67M 12.60M 12.56M 12.35M 12.12M
Earnings Per Share, Diluted $1.75 $1.50 $1.35 $1.02 $0.74 $0.11
Weighted Average Number of Shares Outstanding, Diluted 12.85M 12.78M 12.72M 12.64M 12.59M 12.44M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 51.16M 52.23M 49.76M 57.96M 62.00M 50.07M
Assets, Current 81.20M 75.24M 76.00M 77.49M 76.24M 63.74M
Assets 108.78M 98.33M 92.16M 85.51M 82.88M 71.07M
Liabilities, Current 10.18M 8.51M 16.33M 8.55M 6.82M 4.92M
Liabilities 14.16M 11.51M 20.74M 11.84M 10.71M 9.68M
Stockholders' Equity Attributable to Parent 94.62M 86.82M 71.42M 73.67M 72.17M 61.38M
Common Stock, Shares, Outstanding 12.78M 12.71M 12.66M 12.59M 12.54M 12.31M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 24.95M 25.62M 13.47M 10.04M 11.26M 5.82M
Payments to Acquire Property, Plant, and Equipment 7.76M 8.01M 7.44M 823.02K 482.32K 443.00K
Net Cash Provided by (Used in) Investing Activities -8.42M -8.82M -8.01M -1.37M 648.24K 246.97K
Payments of Dividends 15.04M 13.68M 13.22M 12.56M — —
Net Cash Provided by (Used in) Financing Activities -17.60M -14.34M -13.66M -12.71M 24.43K 522.48K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (IRMD CIK 0001325618), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

AMGN

Amgen Inc.

GENC

GENCOR INDUSTRIES, INC.

POWI

POWER INTEGRATIONS, INC.